<DOC>
	<DOC>NCT00477425</DOC>
	<brief_summary>This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.</brief_summary>
	<brief_title>A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Signed Informed Consent Form Enrollment in one of a list of certain randomized, controlled bevacizumab trials Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD) Congenital long QT syndrome Family history of long QT syndrome Clinically significant bradycardia (defined as &lt; 50 beats/minute)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Avastin</keyword>
</DOC>